{
    "Trade/Device Name(s)": [
        "Stelo Glucose Biosensor System"
    ],
    "Submitter Information": "Dexcom, Inc.",
    "510(k) Number": "K234070",
    "Predicate Device Reference 510(k) Number(s)": [
        "K231081"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "SAF"
    ],
    "Summary Letter Date": "March 5, 2024",
    "Summary Letter Received Date": "December 22, 2023",
    "Submission Date": "December 21, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1355"
    ],
    "Regulation Name(s)": [
        "Integrated Continuous Glucose Monitoring System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Stelo Glucose Biosensor System",
        "Glucose Sensing Subsystem",
        "Mobile Application Subsystem"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical detection",
        "Wire type sensing mechanism",
        "Bluetooth Low Energy data transmission"
    ],
    "Methodologies": [
        "Continuous glucose monitoring"
    ],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "Mobile application",
        "Wearable"
    ],
    "Document Summary": "FDA 510(k) summary for Stelo Glucose Biosensor System, an over-the-counter iCGM for continuous glucose monitoring in adults not on insulin",
    "Indications for Use Summary": "Intended for over-the-counter continuous measurement, recording, analysis, and display of glucose values in people 18 years and older not on insulin; aids detection of normal and abnormal glucose levels and supports lifestyle and behavior modification without providing alerts or dosing guidance.",
    "fda_folder": "Clinical Chemistry"
}